Fading Chen

Fading Chen is a highly skilled professional in the field of neuroscience with extensive experience in both research and leadership roles. Currently serving as the Biology Lead at Frontera Therapeutics since May 2022, Fading Chen manages various therapeutic programs focusing on cardiology, hematology, neurology, ophthalmology, and metabolic disorders. Prior experience includes a role as a Research Scientist at the Broad Institute of MIT and Harvard, where Fading Chen utilized electrophysiological approaches to explore treatments for schizophrenia and studied the functionality of TARPS in PV positive interneurons. Fading Chen's postdoctoral work at Baylor College of Medicine involved pioneering research on the role of astrocyte-derived Clusterin in enhancing excitatory neurotransmission and its therapeutic potential for Alzheimer’s disease. Fading Chen's academic background includes a PhD in Neuroscience from Tulane University, where previous research focused on the regulatory effects of NeuroD2 in synapse development. Early research experience at the National University of Singapore included studies on RNA silencing mechanisms.